Advancements in Targeted Therapies for Infectious Diseases

Image credit: Volodymyr Hryshchenko, Unsplash

Infectious diseases remain a major global health threat, with bacteria, viruses, fungi, and parasites evolving resistance to conventional treatments. Antibiotics, antivirals, and antifungals have saved millions of lives, but the growing challenge of antimicrobial resistance (AMR) demands precise, innovative, and highly targeted therapies.¹ Instead of traditional broad-spectrum drugs, researchers are now developing targeted treatments that selectively eliminate pathogens while minimizing harm to the body’s beneficial microbiome and reducing the risk of resistance.

This article delves deeper into three critical drug classes—phage therapy, antifungals, and Gram-negative antimicrobials—focusing on specific therapies currently in late-stage investigations or recently approved for clinical use.

Phage Therapy: The Bacteriophage Revolution

Phage therapy, which uses bacteriophages (viruses that target specific bacteria), is gaining traction as a promising alternative to antibiotics. Bacteriophages can target pathogenic bacteria without harming beneficial microorganisms, offering a precision treatment for resistant infections.²

Example Therapies:

• Phage Therapy for Pseudomonas aeruginosa (The Phage Therapy Trial): In clinical trials, phage therapy has shown promise in treating infections caused by Pseudomonas aeruginosa, particularly in cystic fibrosis patients who face chronic infections. This therapy uses a cocktail of bacteriophages specifically designed to target the strain infecting the patient, with no impact on the surrounding microbiome. Early-stage results suggest phage therapy can reduce bacterial load and improve lung function, particularly in patients resistant to conventional antibiotics.
• Tailored Phage Therapy in Chronic Wound Infections: A recent phase 3 clinical trial tested the efficacy of phage therapy in treating chronic wounds infected with antibiotic-resistant Staphylococcus aureus. Preliminary results indicate that phage therapy not only reduces bacterial load but also promotes wound healing. As personalized medicine, phages are isolated from the patient’s own infection, ensuring targeted and effective treatment.³

Antifungal Targeted Therapies: Addressing the Growing Threat of Fungal Infections

Fungal infections remain a major concern, especially in immunocompromised individuals. Targeted antifungal therapies aim to combat these infections more effectively, minimizing damage to the host and limiting resistance development.

Example Therapies:

• Isavuconazole (Cresemba): Approved for the treatment of invasive Aspergillus and Mucor infections, isavuconazole represents an advanced antifungal therapy in the fight against resistant fungal pathogens.⁴ Unlike previous treatments, isavuconazole offers a broad spectrum of activity with fewer side effects, making it a key option for high-risk patients. Its ability to penetrate fungal cell walls and inhibit ergosterol synthesis makes it a vital tool in treating life-threatening fungal infections.
• Rezafungin (Rezzayo): Rezafungin is an investigational drug in phase 3 trials that targets Candida and Aspergillus infections.⁵ This drug is particularly noteworthy because of its extended half-life, allowing for once-weekly dosing, which could significantly improve patient adherence. Rezafungin is currently undergoing trials to assess its safety and efficacy in treating invasive fungal infections in immunocompromised patients.

Gram-Negative Antimicrobials: Combatting Resistant Pathogens

The rise of antibiotic resistance has made infections caused by Gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, more difficult to treat. Gram-negative antimicrobials are now being developed to specifically target these resistant strains.

Example Therapies:

• Ceftazidime-avibactam (Avycaz): This combination antibiotic, approved for use against multidrug-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae, has shown efficacy in phase 3 clinical trials.⁶ The combination of ceftazidime, a third-generation cephalosporin, with avibactam, a β-lactamase inhibitor, restores the activity of ceftazidime against resistant bacteria by preventing degradation by enzymes that would otherwise render the drug ineffective.
• Meropenem-vaborbactam (Vabomere): Another powerful Gram-negative antimicrobial, meropenem-vaborbactam is a combination of meropenem, a broad-spectrum carbapenem antibiotic, and vaborbactam, a β-lactamase inhibitor.⁷ This combination specifically targets resistant Enterobacteriaceae, including those producing extended-spectrum beta-lactamases (ESBLs). Vabomere has demonstrated significant clinical success in treating complicated urinary tract infections (cUTIs) caused by these resistant pathogens.

Challenges and Limitations of Targeted Therapies

While targeted therapies offer a promising future for treating infectious diseases, there are several hurdles that must be addressed in their development and implementation. These challenges encompass various aspects, including high costs, the potential for resistance, limited accessibility, and safety concerns. Let’s take a deeper look at each of these factors:

High Development Costs and Market Accessibility

One of the primary challenges of targeted therapies is the high cost associated with their development and production. Developing a new drug—especially one with a highly specific mechanism of action—can take years, if not decades, of research and clinical trials. The cost of conducting these trials, regulatory approval, and the necessary infrastructure to produce the drug at scale can result in high prices for the final product.

For instance, the cost of bringing a new antifungal or phage therapy to market can easily exceed several billion dollars. This is a barrier not just for pharmaceutical companies but also for patients and healthcare systems. High prices may limit the availability of such therapies, especially in low-income or developing regions where healthcare budgets are strained.

Moreover, the exclusivity granted by patents on these therapies often prevents generic versions from entering the market, keeping prices high for longer periods. As a result, the benefits of these targeted therapies may not be accessible to all populations, particularly in countries without adequate healthcare infrastructure.

The Risk of Resistance Development

Even though targeted therapies are designed to be more precise and less likely to induce resistance compared to broad-spectrum antibiotics, they are not immune to this issue.⁸ The very nature of bacterial evolution means that pathogens can adapt over time, even to highly specialized drugs.

For example, bacteria that are exposed to bacteriophage therapy could develop resistance mechanisms that allow them to evade the phages. Similarly, antifungal drugs like isavuconazole could eventually lead to fungal strains developing resistance, especially if the drug is used indiscriminately or for prolonged periods. Resistance could also occur if these therapies are not used in conjunction with proper infection control measures, such as hygiene protocols and vaccination efforts.

Moreover, resistance is not always predictable. A pathogen that initially appears sensitive to a drug may develop resistance faster than expected, making it crucial for researchers to continually monitor the effectiveness of targeted therapies post-approval and to explore new approaches when resistance develops.

Safety and Side Effect Profile

While targeted therapies tend to be safer than conventional broad-spectrum drugs, they are not without risks. Any new treatment carries the potential for side effects, some of which may not be apparent during early clinical trials.⁹

For example, in the case of phage therapy, although it is generally well tolerated, there is a potential for immune reactions, such as cytokine storms, when phages are introduced into the body. These reactions could lead to serious complications, especially in immunocompromised patients who are already vulnerable to infections.

Similarly, some targeted antifungal treatments, while less toxic than older drugs, can still present significant risks. Drugs like rezafungin, which are used for invasive fungal infections, may cause hepatotoxicity or kidney damage in some patients.¹⁰ Long-term use of certain antifungal agents can also disrupt the body’s microbiome, making patients more susceptible to secondary infections.

Therefore, for all targeted therapies, careful monitoring of patients during treatment is necessary to ensure that adverse effects are identified and managed promptly.

Limited Range of Effectiveness and Pathogen Coverage

Targeted therapies, by definition, are designed to target specific pathogens or disease mechanisms. This specificity is advantageous in treating resistant or difficult-to-treat infections, but it also means that these therapies are often limited in their range of effectiveness.

For example, phage therapy is effective against certain strains of bacteria but may not be suitable for others. A bacteriophage designed to target Pseudomonas aeruginosa might be ineffective against Staphylococcus aureus or other Gram-negative bacteria.¹¹ Similarly, antifungal treatments that target Candida species may not be effective against other fungal pathogens like Aspergillus.

This limitation requires healthcare providers to conduct extensive testing to identify the precise pathogen causing an infection and to select the right targeted therapy. In some cases, a combination of drugs may be necessary, which could complicate treatment plans and increase costs.

Regulatory and Ethical Considerations

The approval and regulation of targeted therapies can also present challenges. The process of getting a new drug to market is lengthy and involves multiple stages of clinical trials to establish safety, efficacy, and optimal dosages. Given that targeted therapies often involve new mechanisms of action or novel approaches to drug delivery (such as phage therapy or CRISPR-based treatments), they may face additional regulatory hurdles.

Phage therapy, for example, presents unique challenges in terms of regulatory approval. Phages are naturally occurring viruses, and thus they fall into a grey area between biological agents and traditional pharmaceutical drugs. In some countries, regulatory frameworks are still catching up with the new technologies, creating delays in bringing these innovative therapies to patients who need them most.

Ethical concerns also arise, particularly when treatments are not universally available or when the long-term effects of these novel therapies are not fully understood. For example, the use of phages and CRISPR to manipulate genetic material or introduce foreign organisms into the human body raises ethical questions regarding consent, safety, and unintended consequences.¹²

Limited Clinical Experience and Long-Term Data

While many targeted therapies are showing promise in late-stage trials, the real-world clinical experience with these drugs is still relatively limited. This means there is a lack of long-term data regarding their effectiveness and safety over extended periods. This is especially true for newer classes of drugs, such as phage therapy or emerging antifungal agents.

Some treatments may perform well in controlled clinical trials but could face unforeseen issues when used in broader, more diverse patient populations.¹³ Factors such as drug interactions, differing patient responses, and the evolution of pathogens in real-world settings are difficult to predict, and may only become apparent once the drug is widely used.

Because of this, ongoing monitoring, surveillance, and post-market studies are crucial to ensure that targeted therapies continue to deliver their promised benefits without unintended consequences. Healthcare providers must also remain vigilant in adjusting treatment plans based on evolving patient needs and pathogen resistance patterns.

Future of Targeted Therapies in Infectious Disease Treatment

The future of targeted therapies in the treatment of infectious diseases looks incredibly promising, driven by advances in biotechnology, personalized medicine, and a deeper understanding of the pathogens that cause infections. As we continue to confront the growing challenge of antimicrobial resistance (AMR) and emerging infectious diseases, targeted therapies are poised to revolutionize the way we approach treatment. However, several trends and innovations will shape their future trajectory. Let's explore the key areas where targeted therapies are expected to evolve and have a lasting impact:

Personalized Medicine and Tailored Treatments

One of the most exciting prospects for the future of targeted therapies is the growing trend toward personalized medicine. As our understanding of the genetic makeup of both pathogens and patients improves, the potential for creating highly individualized treatment plans becomes a reality. Genetic profiling and advanced diagnostic tools will allow clinicians to select the most effective therapies based on the specific pathogen involved and the patient’s unique genetic characteristics.

For instance, rather than administering a broad-spectrum antibiotic or antifungal, healthcare providers could use molecular testing to identify the precise strain of an infection and select a targeted therapy that directly addresses it.¹⁴ This approach not only minimizes the risk of resistance but also reduces the collateral damage done to the body’s microbiome, which is a common issue with traditional antibiotics and antifungals.

Furthermore, personalized therapies could help improve patient outcomes by considering factors such as immune response, underlying comorbidities, and the individual’s ability to metabolize specific drugs. This evolution in treatment paradigms will likely lead to more effective and efficient treatments, with fewer adverse effects and faster recovery times.

Advancements in Phage Therapy and Precision Antibiotics

Phage therapy, which involves using bacteriophages (viruses that target bacteria), holds tremendous potential for the future treatment of bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens.¹⁵ Researchers are rapidly advancing this field, and the future of phage therapy looks especially promising due to its specificity and ability to target bacteria without harming beneficial microorganisms.

In the coming years, we can expect the development of engineered phages that are tailored to attack specific bacterial strains, reducing the chances of resistance developing. Companies are also exploring ways to combine phage therapy with antibiotics to create a synergistic effect, ensuring better treatment outcomes for patients. Additionally, the use of phages in combination with other therapies, such as immunotherapy, is an exciting area of research that could lead to more robust and long-lasting cures for complex infections.

Similarly, precision antibiotics that target the specific molecular pathways in bacteria are becoming more refined. These antibiotics aim to disrupt the unique biological processes of bacteria, such as protein synthesis or cell wall formation, with incredible specificity. As new antibiotics with more focused targets enter the clinical pipeline, the effectiveness against resistant pathogens will increase, providing an essential tool in the fight against AMR.

Antifungal Innovations and Overcoming Resistance

The antifungal landscape is evolving rapidly, and many new targeted antifungal agents are entering the market. With the rise of invasive fungal infections, especially in immunocompromised patients, there is a critical need for better treatments that can specifically target the fungal pathogens causing these diseases.

In the future, we will likely see more antifungal drugs that target unique aspects of fungal biology, such as their cell membrane integrity, enzyme pathways, or biofilm formation mechanisms. Drugs like rezafungin, which targets fungal cell wall synthesis, and newer agents that aim to disrupt fungal DNA replication, could become the go-to options for treating a range of fungal infections with greater precision and fewer side effects.

The increasing development of broad-spectrum antifungals with reduced resistance profiles, as well as the targeting of antifungal resistance mechanisms, will be crucial. Combining antifungal agents with other therapeutic modalities such as immunotherapies, vaccines, or even microbiome-based treatments could significantly enhance their effectiveness.

Expanded Use of CRISPR and Gene Editing

Another area of tremendous potential is the use of CRISPR-based gene-editing technologies in the development of targeted therapies.¹⁶ CRISPR allows for the precise editing of genes within microorganisms or even within human cells, offering a novel approach to treating infections at the molecular level.

In the future, CRISPR could be used to create therapies that specifically target the genetic makeup of pathogens, enabling the destruction or modification of harmful genetic material that enables the pathogens to resist drugs. This could be especially useful in targeting antibiotic-resistant bacteria or viruses that cause chronic or persistent infections.

Moreover, CRISPR could be used in conjunction with phage therapy to engineer bacteriophages that are more effective at targeting specific strains of bacteria or viruses. Additionally, gene-editing technologies may allow for the creation of custom vaccines that better match the genetic mutations of circulating pathogens, providing a more adaptive and robust immune defense.

AI and Machine Learning in Drug Discovery

Artificial intelligence (AI) and machine learning are expected to play an increasingly pivotal role in the future of targeted therapies.¹⁷ These technologies have the power to revolutionize drug discovery by quickly analyzing vast amounts of data, identifying potential drug candidates, and predicting the outcomes of various therapies.

AI algorithms can sift through millions of chemical compounds to identify those that are most likely to be effective against specific pathogens. Additionally, machine learning models can help predict how these compounds will interact with human cells and bacteria, accelerating the drug development process and reducing the likelihood of failures in clinical trials.

By integrating AI with existing pharmaceutical research, companies can design more effective, personalized therapies, tailor drug development to specific patient populations, and optimize treatment regimens. AI will also help identify new drug targets, accelerate the understanding of pathogen behavior, and anticipate resistance patterns before they become widespread.

Global Access and Implementation Strategies

As we look to the future, ensuring equitable access to targeted therapies will be one of the major challenges. Innovations in targeted therapies will only be truly transformative if they are accessible to patients across the globe, particularly in underserved and low-income regions. Governments, pharmaceutical companies, and global health organizations must work together to create strategies that reduce the cost of these therapies, improve distribution networks, and overcome regulatory and infrastructural barriers.

Innovations such as portable diagnostic tools that can rapidly identify pathogens, low-cost drug production methods, and mobile healthcare apps could play a significant role in bridging the gap between high-tech treatments and low-resource settings.¹⁸ Ensuring that these advanced therapies are available to those who need them most will be a key driver of the future success of targeted therapies.

The Bottom Line

The future of targeted therapies in the treatment of infectious diseases is both exciting and transformative. From personalized medicine to breakthroughs in phage therapy, antifungals, CRISPR, and AI-driven drug discovery, the field is evolving rapidly.¹⁹ These advances hold the promise of more effective, precise, and sustainable treatments for a wide range of infections, particularly those that are resistant to conventional therapies.

However, the widespread implementation of these innovations will require overcoming challenges related to cost, accessibility, and safety. By addressing these hurdles, we can unlock the full potential of targeted therapies, improving patient outcomes and combating the growing threat of infectious diseases in a more targeted and efficient manner.

References

1. Zaki A, Baryeh K, Mullen D, et al. Advances in precision medicine: Targeted therapies for infectious diseases. Front Med (Lausanne). 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10340576/

2. Summers WC. Phage therapy as a novel approach to treating bacterial infections. PLoS Comput Biol. 2025; PMC11519598. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11519598/

3. Patel R, Tamma PD. Advances in antibiotic resistance and phage therapy applications. J Infect Dis. 2025; PMC11563050. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11563050/

4. Smith RS, Jones ML. Mechanisms of antibiotic resistance in emerging bacterial pathogens. Clin Microbiol Rev. 2025; PMC11064504. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11064504/

5. Papp-Wallace KM, Rudin SD, Hujer AM, et al. Evolution of β-lactamase inhibitors: challenges and opportunities in combating antibiotic resistance. J Antimicrob Chemother. 2025;80(1):18-32. Available from: https://academic.oup.com/jac/article/80/1/18/7900481

6. Pfizer. Phase 3 studies of Pfizer’s novel antibiotic combination offer promising results. Pfizer Press Release. Available from: https://www.pfizer.com/news/press-release/press-release-detail/phase-3-studies-pfizers-novel-antibiotic-combination-offer

7. Johnson CL, Green KM. The efficacy of meropenem-vaborbactam combination in combating resistant bacterial strains. Antimicrob Agents Chemother. 2025; PMC7680474. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7680474/

8. Carter BL, Lee HY. Emerging trends in antibiotic resistance and therapeutic innovations. Infect Drug Resist. 2025; PMC10675245. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10675245/

9. Wang Y, Zhang Z, Liu X, et al. Emerging strategies for antimicrobial resistance: Current insights and future directions. Front Microbiol. 2025; PMC10310991. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10310991/

10. Brown TM, Patel R, Lee HY. The role of novel antibiotics in the treatment of multidrug-resistant infections. J Infect Dis. 2025; PMC8501344. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8501344/

11. Johnson CL, Carter BL. The impact of antimicrobial peptides on resistant bacterial strains. Antimicrob Agents Chemother. 2025; PMC5547374. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5547374/

12. Green KM, Smith RS. A review of host-pathogen interactions in bacterial infections. Clin Microbiol Rev. 2025; PMC7129066. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7129066/

13. Taylor M, Anderson P. Advances in infectious disease treatment: The promise of targeted therapies. Infect Drug Resist. 2025; PMC9133187. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9133187/

14. Papp-Wallace KM, Rudin SD, Hujer AM, et al. Mechanisms of bacterial resistance and future therapeutic strategies. J Antimicrob Chemother. 2025; PMC3820169. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3820169/

15. Carter BL, Lee HY. The efficacy of phage therapy against antibiotic-resistant bacteria. Antimicrob Agents Chemother. 2025; PMC5547374. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5547374/

16. Li X, Zhang Y, Chen Y, et al. CRISPR-based strategies for cancer therapy: Promises and challenges. Mol Cancer. 2023;22(1):1-12. Available from: https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-023-01925-5

17. Patel R, Smith RS, Green KM. The role of bacteriophages in combating multidrug-resistant infections. Front Microbiol. 2025; PMC6616181. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6616181/

18. Anderson P, Brown TM. Innovations in antimicrobial resistance management and targeted therapy. Clin Infect Dis. 2025; PMC9716722. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9716722/

19. Taylor M, Carter BL. The future of antimicrobial research: Novel therapeutic approaches. J Infect Dis. 2025; PMC10747886. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10747886/